 NANJING, China and SAN DIEGO, June 2, 2021 PRNewswire -- GenScript Biotech Corporation HKG: 1548 along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated NASDAQ: LGND announced today that they have entered into a strategic licensing agreement for Ligands OmniAb Platform, a multi-species antibody discovery platform, to generate highly diversified, fully human antibodies that are optimized in vivo for immunogenicity, manufacturability and efficacy. Under terms of the agreement, GenScript is now able to offer its global customers access to the OmniAb rodent platforms for high-quality, rapid, fully human antibody discovery services. 